Published TCIMAIL newest issue No.197
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 97322-87-7 | Product Number: T3920
Troglitazone
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
- 5-[4-[(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]thiazolidine-2,4-dione
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 10MG |
€133.00
|
2 | 13 |
|
| 50MG |
€451.00
|
Contact Us | 3 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | T3920 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__2__4H__2__7NO__5S = 441.54 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Frozen (-20°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Heat Sensitive |
| CAS RN | 97322-87-7 |
| Reaxys Registry Number | 4338399 |
| PubChem Substance ID | 468593021 |
| Merck Index (14) | 9769 |
| MDL Number | MFCD00878416 |
Specifications
| Appearance | White to Orange to Green powder to crystaline |
| Purity(HPLC) | min. 98.0 area% |
Properties (reference)
| Melting Point | 177 °C |
GHS
Related Laws:
| RTECS# | XJ5813130 |
Transport Information:
| HS Number | 2934100090 |
Application
Troglitazone: An Agonist at the Peroxisome Proliferator-Activated Receptor of the Gamma Subtype (PPARγ)
Troglitazone (CS-045), a thiazolidinedione such as rosiglitazone [R0106] and pioglitazone [P1091 (HCl salt)], is an agonist at the peroxisome proliferator-activated receptor of the gamma subtype (PPARγ), a transcription-regulating receptor.1) PPAR receptors are found in peripheral tissues important for insulin action. Activation of PPARγ nuclear receptors modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism. Therefore, troglitazone decreases insulin resistance in the periphery tissues and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. In addition, the PPARγ-independent antitumor effects of troglitazone has been reported.2) Troglitazone was developed as the first in the thiazolidinedione class of hypoglycemic agents, but it was later withdrawn from the pharmaceutical market due to hepatotoxicity.3,4) (The product is for research purpose only.)
References
- 1) The mode of action of thiazolidinediones (a review)
- 2) PPARγ-independent antitumor effects of thiazolidinediones (a review)
- 3) Lessons from the glitazones: a story of drug development (a review)
- 4) Mechanisms of troglitazone hepatotoxicity (a review)
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.